Anti‐CD19 chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study

Author:

Tun Aung M.1ORCID,Patel Romil D.2ORCID,St‐Pierre Frederique3,Ouchveridze Evguenia1,Niu Alex4,Thordardottir Thorunn5,Obasi Jennifer6,Rosenthal Allison7ORCID,Pophali Priyanka A.5ORCID,Fenske Timothy S.6,Karmali Reem3ORCID,Ahmed Sairah2,Johnston Patrick B.4

Affiliation:

1. Division of Hematologic Malignancies and Cellular Therapeutics The University of Kansas Kansas City Kansas USA

2. Department of Lymphoma and Myeloma The University of Texas MD Anderson Cancer Center Houston Texas USA

3. Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center Northwestern University Chicago Illinois USA

4. Division of Hematology Mayo Clinic Rochester Minnesota USA

5. Division of Hematology, Medical Oncology and Palliative Care, Department of Medicine University of Wisconsin Carbone Cancer Center Madison Wisconsin USA

6. Division of Hematology & Oncology Medical College of Wisconsin Milwaukee Wisconsin USA

7. Division of Hematology/Oncology Mayo Clinic Arizona Scottsdale Arizona USA

Abstract

AbstractChimeric antigen receptor T‐cell (CAR‐T) therapy, despite being a potentially curative therapy in relapsed or refractory (RR) large B‐cell lymphoma (LBCL), remains underutilized in older patients due to limited clinical data. We therefore studied the safety and efficacy of CAR‐T therapy in older patients with RR LBCL in the real‐world setting. Patients aged ≥65 years with RR LBCL, treated with anti‐CD19 CAR‐T therapy at 7 US institutions were included in this multicenter, retrospective, observational study. In total, 226 patients were included. Median age at infusion was 71 years (range 65–89). Best objective and complete response rates were 86% and 62%, respectively. Median follow‐up after infusion was 18.3 months. The median progression‐free survival (PFS) was 6.9 months, with 6‐ and 12‐month PFS estimates of 54% and 44%, respectively. The nonrelapse mortality (NRM) rate was 10.9% at day 180, primarily due to infections, and not impacted by the age groups. Grade ≥3 cytokine release syndrome and neurotoxicity occurred in 7% and 26%, respectively. In univariate analysis, no significant difference in PFS was seen regardless of the age groups or CAR‐T type, whereas ECOG PS ≥2, elevated LDH, bulky disease, advanced stage, extranodal involvement, the need for bridging therapy, and prior bendamustine exposure were associated with shorter PFS. These findings support the use of CAR‐T in older patients, including those aged ≥80 years. The age at CAR‐T therapy did not influence safety, survival, and NRM outcomes. Older patients should not be excluded from receiving CAR‐T therapy solely based on their chronological age.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3